logo-loader
viewAstraZeneca

AstraZeneca cancer drug fast-tracked by the FDA

AZ wants to offer Imfinzi to people with late-stage small cell lung cancer

AstraZeneca -

Anglo-Swedish drugs giant AstraZeneca PLC (LON:AZN) has been granted a priority review for a new drug’s use in a particularly aggressive and untreated form of lung cancer.

Imfinzi, which is already prescribed to treat bladder cancer, is being fast-tracked by the US Food & Drug Administration for deployment in patients with late-stage small cell lung cancer.

AZ hopes to have a product on the market early next year.

The application was supported by data from the phase III CASPIAN trial published in The Lancet, one of the world’s leading medical journals.

This showed Imfinzi in combination with the standard chemotherapy extended patients’ lives by a statistically significant three months.

Quick facts: AstraZeneca

Price: 8380 GBX

LSE:AZN
Market: LSE
Market Cap: £109.97 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

World High Life - Proactive One2One Virtual Event

World High Life's (AQSE:LIFE) David Stadnyk and Tony Calamita present to investors at the Proactive One2One Virtual Conference. World High Life is an investment company with a strategic focus to invest in and/or acquire companies operating in the CBD & cannabis industry.

6 hours, 23 minutes ago

2 min read